Deus Technologies debuts lung cancer detector

Article

Deus Technologies will file for premarket approval of an x-ray CAD early-stage lung cancer detection system, joining a growing list of companies that are concentrating on this disease. The product will debut at the RSNA meeting.The stand-alone system,

Deus Technologies will file for premarket approval of an x-ray CAD early-stage lung cancer detection system, joining a growing list of companies that are concentrating on this disease. The product will debut at the RSNA meeting.

The stand-alone system, called RapidScreen RS-2000, uses image processing and feature extraction technology originally employed in the analysis of satellite remote-sensing images. It analyzes regions of interest that may have features associated with solitary pulmonary nodules.

The proprietary algorithms are based on a combination of image processing, neural network, and fuzzy logic techniques developed from a database of thousands of chest films of early-stage lung cancer and cancer-free cases.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.